Search Results for: novartis

Updated: Former Vanderbilt scientist faked nearly 70 images, will retract 6 papers: ORI

A former Vanderbilt University biomedical engineer committed fraud on a massive scale, according to a new Office of Research Integrity (ORI) report. Igor Dzhura is banned from receiving federal funding for three years, and is retracting six papers, which have been cited more than 500 times. Since leaving Vanderbilt, he has worked at SUNY Upstate … Continue reading Updated: Former Vanderbilt scientist faked nearly 70 images, will retract 6 papers: ORI

Ninth retraction appears for cardiology researcher Matsubara

Hiroaki Matsubara, a former Kyoto Prefectural University cardiology researcher who resigned last year following an investigation, has had another paper retracted, his ninth. Here’s the notice from Arteriosclerosis, Thrombosis, and Vascular Biology:

Crystal unclear? “Business decision” forces retraction of silicon paper

A group of researchers in Tokyo has lost their 2013 article in the Journal of Crystal Growth over commercial interests — which don’t appear to be their own. We’ll explain. The article, “Interactions between planar defects in bulk 3C-SiC,” came from a team consisting of a researcher at Keio University and scientists at two companies, … Continue reading Crystal unclear? “Business decision” forces retraction of silicon paper

Weekend reads: A psychology researcher’s confession, a state senator’s plagiarism

Yet another busy week at Retraction Watch, with one of us taking part in a symposium on the future of science journalism for a few days. (See if you can find Ivan in this picture.) Here’s what was happening elsewhere on the web in science publishing and related issues:

Rats! Neuroscientist notches third retraction, this one for using the wrong RNAs

Amine Bahi, a neuroscience researcher in the United Arab Emirates, has had a third paper retracted. Here’s the notice for “Blockade of Protein Phosphatase 2B Activity in the Amygdala Increases Anxiety- and Depression-Like Behaviors in Mice,” which was posted on November 19:

Lancet retracts Jikei Heart Study of valsartan following investigation

The Lancet has retracted a study of Novartis’ blood pressure drug valsartan (Diovan) that has been subject to an investigation following the retraction of a related study earlier this year.

Cardiology journals retract five Matsubara studies

The American Heart Association (AHA) is retracting five studies by Hiroaki Matsubara, a former Kyoto Prefectural University cardiology researcher, that it had subjected to an expression of concern last year. Here’s the notice:

Study of blood pressure drug valsartan retracted

Hiroaki Matsubara, a prominent cardiologist with five Expressions of Concern and two retractions for his CV, has another retraction. As Larry Husten, who first reported the retraction at Forbes, notes, the notice for 2009’s “Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study,” which appeared in … Continue reading Study of blood pressure drug valsartan retracted

Another odd retraction for alcohol researcher, this time for lack of animal research committee approval

The journal Neuroscience has retracted a 2011 paper by an alcohol researcher from the United Arab Emirates, who apparently conducted some mouse studies without the blessing of his institution’s animal ethics officials. At least, that’s what the retraction notice would have us believe. The paper in question, “The pre-synaptic metabotropic glutamate receptor 7 “mGluR7” is a … Continue reading Another odd retraction for alcohol researcher, this time for lack of animal research committee approval